Clinical Trials Directory

Trials / Completed

CompletedNCT00978718

Selenium in Preventing Prostate Cancer

Phase III Trial of Selenium for Prostate Cancer Prevention

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
700 (estimated)
Sponsor
University of Arizona · Academic / Other
Sex
Male
Age
79 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Selenium supplements may stop or delay the development of prostate cancer in patients at high risk of prostate cancer. It is not yet known which dose of selenium may be more effective in preventing prostate cancer. PURPOSE: This randomized phase III trial is studying how well selenium works in preventing prostate cancer.

Detailed description

OBJECTIVES: * To determine whether selenium (Se) supplementation decreases the incidence of prostate cancer. * To determine whether Se supplementation inhibits the biochemical progression of prostate cancer. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms. * Arm I: Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer. * Arm II: Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer. * Arm III: Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer. Blood samples are collected at baseline, at randomization, and then semi-annually for laboratory and other testing. Tissue samples may also be collected for biomarker analysis. Patients complete an initial questionnaire and urological-symptoms questionnaire at baseline, a follow-up questionnaire after randomization (to capture new illness, medications, and toxicity symptoms during the 30-day run-in period; a urological-symptoms questionnaire; a food-frequency questionnaire; and a mood questionnaire). Patients then undergo questionnaires semi-annually, including vital status, tablet compliance, nutrition, mood, new illnesses or medications, and any incidence of cancer or family history of cancer).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENThigh-selenium baker's yeastGiven orally
DIETARY_SUPPLEMENTseleniumGiven orally
OTHERplaceboGiven orally

Timeline

Start date
2001-08-01
Primary completion
2004-06-01
Completion
2004-06-01
First posted
2009-09-17
Last updated
2012-08-15

Source: ClinicalTrials.gov record NCT00978718. Inclusion in this directory is not an endorsement.